Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 17/20 | 0.76 |
| ▸ | INSR | P06213 | 6/20 | 0.76 |
| ▸ | ROS1 | P08922 | 6/20 | 0.76 |
| ▸ | IGF1R | P08069 | 5/20 | 0.76 |
| ▸ | EGFR | P00533 | 4/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.76 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.76 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.76 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.76 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.76 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.76 |
| ▸ | PLK4 | O00444 | 2/20 | 0.76 |
| ▸ | GAK | O14976 | 2/20 | 0.76 |
| ▸ | ERN1 | O75460 | 2/20 | 0.76 |
| ▸ | STK10 | O94804 | 2/20 | 0.76 |
| ▸ | ABL1 | P00519 | 2/20 | 0.76 |
| ▸ | LCK | P06239 | 2/20 | 0.76 |
| ▸ | FYN | P06241 | 2/20 | 0.76 |
| ▸ | FES | P07332 | 2/20 | 0.76 |
| ▸ | YES1 | P07947 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493421 | 1.00 | ALK (0.76) | ALKINSRROS1IGF1REGFR | |
| SCHEMBL22493198 | 0.99 | ALK (0.77) | ALKINSRROS1IGF1REGFR | |
| SCHEMBL22493199 | 0.93 | ALK (0.73) | ALKINSRROS1IGF1REGFR | |
| SCHEMBL22493200 | 0.93 | ALK (0.78) | ALKINSRROS1IGF1REGFR | |
| SCHEMBL22493385 | 0.91 | ALK (0.82) | ALKINSRROS1IGF1REGFR | |
| SCHEMBL22493362 | 0.87 | ALK (0.76) | ALKINSRROS1IGF1REGFR | |
| Tae-684 SCHEMBL282775 | 0.86 | ALK (1.00) | ALKINSRROS1IGF1REGFR | |
| Tae-684 SCHEMBL29641017 | 0.86 | ALK (1.00) | ALKINSRROS1IGF1REGFR | |
| SCHEMBL4098937 | 0.86 | ALK (0.85) | ALKINSRROS1IGF1REGFR | |
| SCHEMBL24301100 | 0.85 | ALK (0.87) | ALKINSRROS1IGF1REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | ADRM1, VHL, MDM2 | ALK 5/4885INSR 1929/4885ROS1 78/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | ALK 5/4885INSR 1929/4885ROS1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.